Gyre Therapeutics (GYRE) SEC Filings: History & Chart

Gyre Therapeutics, Inc.(GYRE)

Biotechnology · San Diego, CA

$7.19-0.17 (-2.24%)

Delayed quote: Oct 6, 2026, 2:40 PM EDT

About Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.

San Diego, CA

625 employees

www.gyretx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ying Luo

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 1, 2026	Sep 1, 2026	View filing
S-8	Aug 31, 2026	Aug 28, 2026	View filing
8-K	Aug 26, 2026	Aug 26, 2026	View filing
10-Q	Aug 7, 2026	Aug 7, 2026	View filing
8-K	Aug 7, 2026	Aug 7, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
3	Aug 4, 2026	Aug 4, 2026	View filing
3	Aug 4, 2026	Aug 4, 2026	View filing
EFFECT	Aug 3, 2026	Aug 4, 2026	View filing
8-K	Jul 16, 2026	Jul 16, 2026	View filing
8-K/A	Jul 15, 2026	Jul 15, 2026	View filing
S-3/A	Jul 13, 2026	Jul 13, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
S-3	Jun 23, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
8-K	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
S-8	Jun 10, 2026	Jun 9, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
8-K	Jun 2, 2026	Jun 2, 2026	View filing
4	May 27, 2026	May 27, 2026	View filing

SEC Filings

Recent Filings